about
Chronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis.Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.Clinical significance of somatic mutation in unexplained blood cytopenia.Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance.Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors.Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphase-FISH.Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma.Development of a Richter syndrome with a monoclonal component from a true B-cell chronic lymphocytic leukemia (B-CLL) treated with fludarabine.An insidious presentation of splenic marginal zone lymphoma.The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms.Immunogenetics features and genomic lesions in splenic marginal zone lymphomaImpact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines?HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemiaHigh-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphomaBiological markers and prognostic scoring systems in chronic lymphocytic leukaemiaCLLU1 expression distinguishes chronic lymphocytic leukemia from other mature B-cell neoplasmsIGHV unmutated status influences outcome more than IGHV1-69 gene usage per se in patients with chronic lymphocytic leukemiaA risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to WaldeJAK inhibitors and risk of B-cell lymphomasClinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) networkRuxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms
P50
Q35925580-1E7268F2-DCE4-4C5D-969C-DED5F1445C0CQ38442976-43300CCD-F212-4B8D-9ED9-131927CBDA1CQ40892006-B28665BD-09A6-4C0F-A2D8-EDA51881DCF8Q41240561-1A065FF9-0A86-496C-837C-E254A68E1FD0Q42639007-4B85B455-A536-4760-8D24-06B23B9939F2Q43417443-F47FDABA-B373-40D8-B49D-897FCE2B8B46Q43706086-7DCB5077-D222-46F5-B886-2A7B2EE95AB0Q43763021-4B60F34C-D299-4F4D-9C40-ACC12C7252F3Q47140051-34B151E5-F29E-4AFF-A079-5732D615977BQ51483185-CF12C7AC-0774-4DB9-AD00-09C445B4CEC1Q53335828-A7D23EEF-44F1-44E5-B26D-40E8A71FC6CDQ53541876-4BA4AE8C-C094-4A1D-AF1E-44473FD3E929Q54339929-DA272E80-F2E2-4A75-B7CC-D855F458AEE3Q58000976-C9DEF121-67B5-423A-996F-1206FC19C137Q58041988-23A14E38-F657-413A-A1A8-97A905CC6523Q80206218-AE6BE566-B9A1-4403-8E37-4E967746C350Q84333293-259CEB2A-A39E-4E34-B1D6-A0BFEE212A5CQ84437902-9839841F-546D-4D7D-A152-79D656FB3079Q84472487-575247D6-88FB-4C45-AABB-53560B8D2BAAQ84785477-3E990204-0BD9-4D3E-8819-10CA3820DB6CQ91647581-50466F61-BE39-4C80-AFA8-91749BFA9BEBQ92253456-F71876C6-B437-48BA-BCBD-916D17E5A9D2Q92398628-85D92FEC-DF74-42DC-9675-14C9F8690627Q93018531-71E7FB30-D193-42F3-846D-E3D9752A05B9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Silvia Zibellini
@ast
Silvia Zibellini
@en
Silvia Zibellini
@es
Silvia Zibellini
@nl
type
label
Silvia Zibellini
@ast
Silvia Zibellini
@en
Silvia Zibellini
@es
Silvia Zibellini
@nl
prefLabel
Silvia Zibellini
@ast
Silvia Zibellini
@en
Silvia Zibellini
@es
Silvia Zibellini
@nl
P106
P1153
16235384400
P31
P496
0000-0002-1527-363X